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Traumatic brain injury (TBI) has been increasingly accepted as a major external risk
factor for neurodegenerative morbidity and mortality. Recent evidence indicates that
the resultant chronic neurobiological sequelae following head trauma may, at least
in part, contribute to a pathologically distinct disease known as Chronic Traumatic
Encephalopathy (CTE). The clinical manifestation of CTE is variable, but the symptoms
of this progressive disease include impaired memory and cognition, affective disorders
(i.e., impulsivity, aggression, depression, suicidality, etc.), and diminished motor control.
Notably, mounting evidence suggests that the pathology contributing to CTE may
be caused by repetitive exposure to subconcussive hits to the head, even in those
with no history of a clinically evident head injury. Given the millions of athletes and
military personnel with potential exposure to repetitive subconcussive insults and TBI,
CTE represents an important public health issue. However, the incidence rates and
pathological mechanisms are still largely unknown, primarily due to the fact that there
is no in vivo diagnostic tool. The primary objective of this manuscript is to address
this limitation and discuss potential neuroimaging modalities that may be capable of
diagnosing CTE in vivo through the detection of tau and other known pathological
features. Additionally, we will discuss the challenges of TBI research, outline the known
pathology of CTE (with an emphasis on Tau), review current neuroimaging modalities to
assess the potential routes for in vivo diagnosis, and discuss the future directions of CTE
research.
Keywords: Traumatic brain injury (TBI), Tau, Chronic Traumatic Encephalopathy (CTE), neuroimaging, concussion,
Positron Emission Tomography (PET)
Introduction
There has been a recent explosion of research focused on improving the diagnosis and treatment
of Traumatic Brain Injury (TBI). The discourse has shifted to potential long-term effects following
recent evidence in high-profile professional athletes linking head injuries with Chronic Traumatic
Encephalopathy (CTE). The general population has gained a better understanding of TBI with
heightened public awareness spurred, in large measure, by these high-profile cases. Meanwhile the
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medical community has made a concentrated effort on discovery
with new research initiatives. However, with this heightened
attention and national media coverage it is important that
discussions carefully delineate evidence confirmed by empirical
studies from hypotheses about this neurodegenerative disease
process and its potential link to head trauma (DeKosky et al.,
2010). Given the human brain’s vast complexity and seemingly
endless intricacies, it is of little surprise that many unknowns
remain about TBI.
The Challenging Landscape of TBI Research
The challenge with investigating TBI begins with its definition
(Tator, 2014). There are major differences in how various
organizations define and classify head injuries, which have
obscured treatment and research (Ruff et al., 2009). For instance,
within a single panel of experts, The International Conference
for Concussion in Sport, the operational definition of TBI has
changed each of the four times the panel has met over the
past decade (Aubry et al., 2002; McCrory et al., 2005, 2009).
The definition of TBI has not kept pace with our rapidly
evolving understanding of the injury and thus, the diagnosis of
TBI remains vague. For the purposes of this article, the term
concussion will be used interchangeably with mild TBI (mTBI),
defined as a closed brain injury that results in specific clinical
symptoms, generally from self-report, such as altered sensorium
and loss of consciousness.
Amidst the ambiguity surrounding TBI and its definition, the
data available indicates it is prevalent in all segments of society
and is escalating in frequency. In the CDC’s most recent report,
TBI was referred to as a “silent epidemic” for it is widespread and
often undetectable sequelae (Faul et al., 2010). TBI is currently
the leading cause of morbidity and mortality worldwide in
individuals under the age of 45 (World Health Organization,
2006). The World Health Organization (WHO) reports an
estimated 10 million people suffer TBIs annually and predicts
that TBI will be the third largest contributor to the global burden
of disease and mortality by 2020 (World Health Organization,
2006). According to the CDC, falls are the most frequent cause
for TBI accounting for roughly 35% of head injuries (Faul
et al., 2010). People over 60 are at greater risk for these falls
and, therefore, TBIs can be expected to increase given that this
demographic group is projected to grow 223% between 1970
and 2025 to totaling 1.2 billion (Kalache and Gatti, 2003). The
WHO reports that vehicular accidents are occurring at higher
rates around the world as developing nations continue to adopt
motorized forms of transportation that lack adequate regulations,
safe roads, and safe equipment (World Health Organization,
2006). Recent estimates also indicate that recreational sports
account for 1.6–3.8 million TBI each year in the United States
alone (Langlois et al., 2005), a number that is up from 306,000
in 1991 (Thurman et al., 1998). Additionally, a higher-percentage
of soldiers are experiencing TBI as new innovations in medicine
(e.g., craniectomies, control of hemorrhagic bleeding) and their
body armor make it more likely to survive injuries that would
have previously proved fatal without adequately protecting their
head (Okie, 2005). Laboratory studies of animals are helping
to better understand the biomechanical forces associated with
blasts, but more research is required to better understand the
acute and chronic effects of these events (Cernak et al., 2011;
Rubovitch et al., 2011; Wang et al., 2011; Goldstein et al., 2012;
Xiong et al., 2013). Head injuries are so prevalent amongst this
population that mTBI has been called the signature injury of the
recent wars in Iraq and Afghanistan with an estimated 10–20% of
all soldiers sustaining such injuries (Hoge et al., 2008; Elder and
Cristian, 2009).
Despite their growing prevalence, concussions suffer a
problem of perception; they are invisible injuries with no
overt signs (e.g., surface wounds, broken bones) and patients
rarely associate their symptoms with the traumatic incident
making it exceedingly difficult for physicians to objectively
measure (Nowinski, 2013). The subjective and equivocal nature
of TBI often leads to misdiagnosis. Currently, clinicians diagnose
concussions based on self-report of chronic symptoms that may
include headache, nausea, vomiting, dizziness, fatigue, abnormal
sleeping patterns, drowsiness, impaired memory/cognition, and
more (McCrory et al., 2009; Randolph and Kirkwood, 2009;
Randolph et al., 2009). Additionally, the clinical diagnosis
relies on self-report of acute symptoms from patients, which is
inherently unreliable (Delaney et al., 2002; McCrea et al., 2004).
Though there is considerable debate and the exact prevalence
is not entirely understood, approximately 10–15% of those
diagnosed with concussions go on to develop post-concussive
syndrome (PCS) where these symptoms persist for at least 3
months following the injury (Bigler, 2008; Williams et al., 2010).
Additionally, there is often a delayed manifestation of symptoms,
which leaves the patient less likely to associate their symptoms
with the injury and omit medical care (Roozenbeek et al., 2013).
It has been widely reported that a significant portion of those
suffering head injuries do not seek medical attention because
(1) patients are unaware of the symptoms constitute a TBI
or, (2) disincentives for reporting symptoms leads patients to
intentionally conceal the incident to remain engaged in their
activity (e.g., sports, combat) (Langlois et al., 2005, 2006). Experts
have explored the utility of neuroimaging techniques to assist in
diagnosis, but a reliable diagnostic imaging biomarker for mTBI
remains elusive. Physicians may use conventional Magnetic
Resonance Imaging (MRI) or Computed Tomography (CT)
scans at the time of clinical assessment, but the Diffuse Axonal
Injuries (DAI) often present inmild TBI are undetectable by these
techniques (Shenton et al., 2012). The integration of kinematic
data from accelerometers to assist with diagnosis has also been
explored, but this practice has proven to be inadequate to date
(Guskiewicz and Mihalik, 2011).
These limitations and challenges in the diagnosis of head
injuries are problematic at a number of levels. First, those who
experience neurological damage following trauma to the head
may be in serious danger of second impact syndrome, which
remains controversial in its own right due to its low incidence
and the imperfect measures discussed above to identify the
primary injury required to precede it (Bey and Ostick, 2009).
Additionally, it is well established that those with a history of
TBI are more susceptible to future injuries (Guskiewicz et al.,
2000; Abrahams et al., 2014) and, therefore, should alter their
behaviors or be observed with greater scrutiny if they choose
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to continue any activity that may presents a risk for repeat
injury. Furthermore, effects of these injuries may accumulate as
exposure to head trauma increases so patients should be aware of
all prior head injuries in order to make informed decisions about
their future actions (Guskiewicz et al., 2003). Lastly, undiagnosed
concussions can adversely affect future medical management and
confound research results (Carroll et al., 2004; Roozenbeek et al.,
2013).
Emerging Neuroimaging Techniques
Although, conventional MR and CT scans are unable to
detect the microscopic damage occurring with DAI, new
neuroimaging techniques are emerging that may yield key insight
to microstructural changes in the brain following TBI. Diffusion
Tensor Imaging (DTI) is a non-invasive MRI method that
is sensitive to the microscopic alterations of neuronal tissue,
specifically occurring in the white matter (WM) of the brain.
DTI relies on the diffusion properties of water to generate
measures indicative of the structural integrity of specific WM
structures within the brain in vivo. For example, movement
of water in cerebrospinal fluid (CSF) is unrestricted and,
therefore, it is free to diffuse in all directions (isotropic). WM,
however, is encapsulated by myelin sheaths, neurofilaments,
microtubules, and axonal membranes that restrict diffusion to
the direction in which the axon is oriented (anistropic). The
two primary indexes of DTI are Fractional Anisotropy (FA) and
Mean Diffusivity (MD), which measure the directionality and
magnitude of diffusion, respectively. Reduced FA and increased
MD measures are thought to be indicative of impaired WM
structural integrity. Two additional measures generated by DTI
are radial diffusivity (RD) and axial diffusivity (AD), which,
although still debated, are thought to be indicators of myelin and
axonal health, respectively (Wheeler-Klingshott and Cercignani,
2009). Researchers are also interested in examining the functional
impairments DAIs may cause to the brain. Functional MRI
(fMRI), is capable of observing these effects by utilizing Blood
Oxygen Level Dependent (BOLD) measures in specific regions
of the brain, either in response to a cognitive challenge (task) or
during the resting state.
Many studies are implementing these emerging neuroimaging
modalities to examine the structural and functional damage
in vivo that is consequential to head trauma. Studies utilizing
FA, MD, RD, and AD indexes to measure the structural integrity
of WM structures throughout the brain consistently show long
lasting damage following TBI (Inglese et al., 2005; Salmond
et al., 2006; Kraus et al., 2007; Lipton et al., 2008; Miles et al.,
2008; Niogi et al., 2008; Little et al., 2010; Cubon et al., 2011;
Ljungqvist et al., 2011; Davenport et al., 2012; Taber et al.,
2015). Studies have found significant correlations between the
extent of WM damage and the severity of TBI (Matsushita et al.,
2011), number of TBI (Davenport et al., 2012), and impaired
cognitive function (Salmond et al., 2006; Miles et al., 2008;
Niogi et al., 2008). Notably, several of these studies showed
no brain damage with the conventional MR and CT scans
currently used for diagnosis at the time of initial examination.
However, it is worth noting that acute studies utilizing DTI
immediately following head injury have produced conflicting
results (Mayer et al., 2010; Henry et al., 2011). Until the
relationship between acute and chronic alterations to the brain’s
WM following TBI is better understood, it will be difficult to
utilize DTI as a diagnostic tool. Additionally, most of the studies
utilizing neuroimaging modalities to study TBI are currently
only able to observe significant between-group effects of TBI,
but refining these methods to accurately characterize damage to
brain tissue at the individual level is the topic of active ongoing
research.
Subconcussive Head Impacts
Although shortcomings related to the clinical diagnosis and
definition of TBI are troublesome and need to be addressed,
emerging research suggests that a medically documented history
of TBI is not necessary to experience the long-term sequelae
of head injuries. Accumulating evidence suggests that frequent
exposure to subconcussive blows to the head, even in populations
with no history of concussions, can substantially hamper
neuronal health (Dashnaw et al., 2012). Recently, researchers
have attempted to examine the extent to which this accumulative
damage in the brain can occur following subconcussive events,
which are defined as blows to the head generating enough force to
disrupt neuronal integrity without resulting in clinically evident
symptoms. Athletes, particularly those participating in contact
sports, are being studied for the effects of subconcussive hits.
For example, both collegiate and high school football players
are known to experience hundreds, if not thousands, of sub-
concussive hits in a single season with an average of 652 hits
exceeding 15 g of force (Broglio et al., 2009, 2011; Crisco
et al., 2011). There is some concern regarding the validity of
studies investigating the effects of subconcussive blows since the
events are difficult to define objectively. However, data from
accelerometers and access to video recordings have helped to
mitigate concerns by limiting the reliance on the inaccurate
self-report from athletes.
The contention that subconcussive blows can impair neuronal
health is supported by studies utilizing DTI and fMRI to
investigate the alterations in the brain’s structural and functional
connectivity in vivo. One DTI study reported evidence of soccer
players with significantly impaired WM integrity compared to
a group of swimmers who experienced no head trauma (Koerte
et al., 2012a). These findings were supported by a study that found
the frequency with which soccer players make head contact with
the ball is significantly related to both WM damage and, in turn,
cognitive impairments (Lipton et al., 2013). Longitudinal studies
observing athletes over the course of a single season also indicate
that frequent exposure to head trauma, even at subconcussive
levels, may have deleterious effects on neuronal health. Ice
hockey players were shown to exhibit significant decreases
in WM integrity over the course of a single season (Koerte
et al., 2012b). In college football players, postseason measures
of WM integrity were significantly worse than both postseason
measures for noncontact athletes and preseason measures for
both groups (McAllister et al., 2014). Additionally, this cohort’s
head impact exposure (measured by a helmet accelerometer)
was correlated with a decrease in WM integrity and impaired
cognitive function (McAllister et al., 2014). Another study
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observed similar changes in WM integrity between pre-season
and post-season measures, but further reported that much of
these deleterious effects persist chronically after 6 months of
no-contact rest (Bazarian et al., 2014). We previously reported
chronic structural neuronal damage assessed with DTI in recent
military veterans (Iraq and Afghanistan) with blast exposure,
even in the absence of a clinically evident concussion (Taber et al.,
2015).
Functional impairments are also detected in populations
with repetitive exposure to subconcussive insults. Two
separate studies demonstrate that high school football players
with no clinically evident symptoms of concussion had
worsened neurocognitive measures and significant changes to
neurophysiology as measured by fMRI (Breedlove et al., 2012;
Talavage et al., 2014). Interestingly, this functionally impaired
group consisted mostly of linemen, who experience head to
head contact at subconcussive levels on nearly every play from
scrimmage. Another study employed fMRI to examine the
chronic effects of this cumulative damage by investigating a
cohort former National Football League (NFL) players who
were an average age of 53 years old. The results indicate that
this clinically normal cohort of former NFL players exhibited
functional hypoconnectivity during resting state fMRI and
hyperactivation of brain regions during cognitive tasks in fMRI
compared to controls (Hampshire et al., 2013). This finding of
hyperactivation during mental tasks could be a compensatory
mechanism for brain to overcome the structural damage outlined
above in separate DTI studies. These functional and structural
impairments observed over the course of a single season are
unnerving, especially when considering the collective damage
that must be occurring over the course of an entire career (either
amateur or professional).
It has been demonstrated that both concussive events and
frequent exposure to subconcussive insults result in deleterious
effects to the brains structural and functional capacity, often
resulting in cognitive impairments. These are significant findings
on their own, however, it is essential to take this line of research a
step further by examining the effect of damage from head trauma
on neurodegenerative diseases later in life. It has been postulated
that TBI and repetitive subconcussive events deplete the brain’s
functional capacity that conspires with aging to push the brain
below the threshold for dementia and neurodegenerative disease
(Lehman et al., 2012; Bigler, 2013; Smith, 2013; Smith et al.,
2013). Across the spectrum of neurodegenerative diseases, there
is a unique, complex etiology for each of the conditions and
future research is required to better understand the extent to
which history of head trauma might factor in to the equation.
It should be noted, the ambiguity surrounding the diagnosis and
definition of TBI confounds results of studies investigating the
long-term effects of head injuries related to neurodegenerative
diseases. The inaccurate incidence of TBI is a limitation for all
studies investigating any potential correlation, but we are hopeful
that improved neuroimaging techniques will help address this
limitation by providing more accurate means for diagnosis of
concussions at the time of injury. Readers should be aware of
this current limitation as they review the following discussion on
CTE.
Chronic Traumatic Encephalopathy
CTE is a progressive neurodegenerative disease derivative of
the cumulative pathophysiological damage incurred by head
trauma. The first clinical manifestations are insidious, but
typically marked by deterioration in attention, concentration and
memory that are often accompanied by disorientation, dizziness,
headaches, and mood disorders. As the disease progresses, more
prominent symptoms begin to manifest including impulsivity,
mood lability, impaired judgment, and overt dementia. In later
phases of CTE, these symptoms continue to worsen and are
accompanied by impaired motor control which can resemble
Parkinsonism with bradykinesia, staggered gait, and vertigo
(McKee et al., 2009; Stern et al., 2011). Importantly, the clinical
progression of CTE is exceedingly difficult to delineate given
that, at this time, diagnoses are not able to be made until post-
mortem examination. Therefore, the timeline of symptoms are
only available from reports collected from family members of
the deceased individuals. Symptoms of drug and alcohol abuse,
frequently comorbid with CTE due to impaired decision making
and impulse control, pose additional clinical challenges with
diagnosis (Gavett et al., 2011). Given these limitations, little
is known about the progression of CTE, but it appears that
symptomsmanifest earlier than other neurodegenerative diseases
with the average age of onset between 30 and 50 years and the
youngest confirmed case of CTE occurred at 18 years (McKee
et al., 2010; Baugh et al., 2012).
Before discussing CTE further, it is important to highlight the
current state of CTE research that has produced controversy in
the field. Themethodological limitations specific to case selection
bias present in autopsy based studies can obscure the validity
of these findings. There are no appropriately matched healthy
controls available to perform direct comparative studies and
therefore, while there is strong support, definitive conclusions
cannot be made about the potential risk of developing CTE
from contact sports and head injuries. It should be noted,
however, that every pathologically confirmed case of CTE has
at least some history of head trauma, though the severity and
frequency of their head injury history is variable (Maroon
et al., 2015). Additionally, until recently there were no validated
neuropathological criteria to define CTE, which is an entirely new
limitation that reduces reproducibility across research groups
(Gardner et al., 2014). In April 2015, however, the first set
of pathologic criteria for CTE were published as a result of
the NINDS/NIBIB consensus meeting sponsored by the NIH
(National Institute of Neurological Disorders and Stroke, 2015).
Thus, the development of standard pathological criteria for this
disease took a major step forward.
Though these limitations make it nearly impossible to
investigate the incidence of CTE, neuropathologically confirmed
cases of CTE have been observed post-mortem in athletes who
were former participants of America football, ice hockey, soccer,
and wrestling (Matser et al., 1998; McKee et al., 2009, 2014, 2013;
Omalu et al., 2005, 2006, 2010a,b, 2011). Cases of CTE have also
been verified in military veterans with blast exposure (Omalu
et al., 2011; McKee et al., 2013) and those with history of self-
injury (Hof et al., 1991) or domestic abuse (Roberts et al., 1990b).
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Researchers at the VA-BU-SLI Brain Bank published the most
extensive study to date documenting the pathology present in
the first 85 brains donated by families of deceased athletes and
military veterans, 68 of which were found to be positive for CTE.
Furthermore, within this sample, 34 of 35 professional football
players were positive for CTE, along with 9 of 9 collegiate players
and 4 of 4 ice hockey players (McKee et al., 2013). Notably, it
is difficult to extrapolate this data and these numbers are not
likely to be representative of disease prevalence within these
populations since these case series are highly selective, with tissue
procurement often preceded by an abnormal event.
It appears that the scientific community is making strong
strides to understand the pathology of CTE, but researchers are
also keen to determine the major risk factors for developing
this condition. There have been cases of CTE after a single TBI,
multiple TBIs, and even with no documented TBIs when the
patient reported significant exposure to subconcussive insults
(McKee et al., 2014). However, the poor correlation between the
number of clinically documented concussions and CTE leaves
this question open for debate. Nowinski and Cantu assert that
CTE is best correlated with “total brain trauma,” which can be
defined as a combination of subconcussive and concussive events
(Nowinski, 2013). It is still unclear how other factors like gender,
age at youngest head injury, and education may influence risk of
developing this disease. Other environmental risk factors include
exposure to neurotoxins like glyphophosate, which are found in
herbicides, and addiction to methamphetamines (Sekine et al.,
2008; Morley and Seneff, 2014). There may also be an inherent
risk for CTE that is determined by genetic make-up. Specifically,
the E4 allele of the APOE gene has received the most attention
and, though the existing literature is inconclusive, it may be
associated with increased risk of CTE (McKee et al., 2009, 2010;
Gavett et al., 2011).
CTE Progression
Researchers at Boston University School of Medicine, at the
largest CTE research center in the world, have proposed a staging
system for the progression of CTE pathology after performing
post-mortem examinations on ∼85 brains (McKee et al., 2013,
2014). Table 1 outlines the pathology that characterizes this
disease according to those proposed stages, which will need
further validation given that they are based solely on retrospective
clinical information on a relatively small sample size. For a more
detailed review on pathology of CTE, see (McKee et al., 2013).
It is important to note that the proposed progression stages
based primarily on the findings of one group and there may
be variability across research groups. To highlight this disparity,
data from the seminal CTE study conducted by Corsellis et al.
(1973), which investigated the brains of boxers, was re-examined
by Roberts et al. who reported in 1990 that Aβ was present
in 95% of the confirmed cases of CTE (Roberts et al., 1990a).
This is substantially higher than reported by McKee et al. who
conclude that Aβ may be present in CTE, but it is not a required
diagnostic feature of the disease. The recent NIH consensus
statement reflects this notion Aβ is not a fundamental criteria for
CTE confirmation (National Institute of Neurological Disorders
and Stroke, 2015).
Distinguishing Pathological Features of CTE
It is essential for researchers to compare the pathological findings
associated with CTE to other neurodegenerative diseases. There
is significant overlap between CTE and other tauopathies,
like Alzheimer’s disease (AD), which has benefits as well as
disadvantages. Knowing that similarities exist between CTE
and AD makes it less daunting; there is a plethora of
research on the disease processes and diagnostic methods of
AD that researchers can use for devising diagnostic methods
for CTE. However, it is vital to differentiate CTE from
other neurodegenerative diseases so they can be properly
diagnosed and treated. The recent consensus statement goes
a long way. A team of neuropathologists were required to
differentiate between digitized slides from 25 cases of tauopathy
including CTE, Alzheimer’s disease (AD), Parkinson-dementia
complex of Guam, progressive supranuclear palsy, corticobasal
degeneration, primary age-related tauopathy, and argyrophilic
grain disease (National Institute of Neurological Disorders and
Stroke, 2015).
Tau
Many neurodegenerative diseases, including CTE, are
characterized by the abnormal deposition of insoluble proteins
throughout the CNS. Indeed, Tau is the primary protein involved
in its pathology, though it should be noted that this pathology
is complex and varied. It is important to note that Tau in its
normal, microtubule bound state is not harmful. In fact, Tau is
ubiquitous in the healthy adult brain as it is the most abundant
microtubule-associated protein (MAP). In this state, Tau
promotes the assembly and maintenance of microtubules, which
are responsible for intracellular transport, axonal morphology,
and cell physiology, all of which signify that Tau is fundamental
in maintaining neuronal integrity and axoplasmic transport
(Tolnay and Probst, 2003; Amadoro et al., 2006; Williams, 2006).
Tau can exist as six isoforms, all of which are generated from
a single gene. These six isoforms differ in the number of N-
terminus inserts (0N, 1N, or 2N) and by the presence of either
three or four C-terminal microtubule binding repeats (3R or 4R).
The presence of 3R and 4R Tau is determined by the inclusion or
exclusion of exon10 (Schmidt et al., 2001) and in the healthy adult
brain there is an equal ratio of 3R and 4R Tau (Goedert, 2004).
Proper functioning of Tau depends on the balance of different
Tau isoforms, its state of phosphorylation, and its structural
integrity. A perturbation of these parameters may cause Tau
dysfunction, ultimately resulting in neurodegeneration (Shahani
and Brandt, 2002). Tau becomes harmful when it is no longer
bound to microtubules, accumulating as insoluble neurofibrillary
tangles (NFTs) in cell bodies and dendrites (Goedert, 2004).
Conditions characterized by this abnormal accumulation of Tau
share the umbrella term tauopathy. Each tauopathy has a unique
series of molecular events in their pathogenic cascade resulting
in a conformational change to the structure of the protein. This
manifests as either an imbalanced ratio of 3R and 4R variants
of Tau or in an abnormal phosphorylation state (Williams,
2006).
The exact mechanisms are not entirely understood, but
it appears that Tau may have deleterious effects when it
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TABLE 1 | Stages of CTE proposed by McKee et al. (2013).
Gross Tau Other Clinical symptoms
Stage I None NFTs at depths of cerebral sulci of the frontal
cortex
TDP-43 inclusions within
sub-cortical white matter
and fornix
Mostly pre-clinical
Some insidious symptoms like
headache, depression, attention loss
Stage II Mild enlargement of lateral and 3rd
ventricles
NFT in subcortical white mater, medial
temporal lobe, brainstem
Rarely amyloid beta found Pronounced behavioral/personality
changes
Cavum septum pellucidum Short term memory loss
Pallor of LC and SN
Stage III Reduced brain weight NFTs present diffusely in frontal, temporal and
parietal cortices. Often concentrated around
small vessels and depths of sulci
TDP-43 inclusions now
present in cerebral cortex,
medial temporal lobe,
diencephalon, and
brainstem
Memory loss, overall cognitive
impairments
Mild frontal/temporal atrophy Aggression, mood disorders
Enlargement of lateral and 3rd
ventricles
NFTs present in subcortical structures:
hippocampus, entorhinal cortex, amygdala,
Nucleus Basalis of Meynart, LC, hypothalamus,
mammillary bodies, SN, Raphe nuclei.
Aβ in 13% of cases 75% considered cognitively impaired
Pallor of LC and SN
Atrophy to mammillary bodies,
thalamus, hypothalamus, thinning of
corpus callosum
Rarely present in spinal cord and dentate
nucleus of cerebellum
Stage IV More pronounced reduction in brain
weight
Widespread degeneration resulting from severe
NFT deposition.
TDP-43 deposition is more
widespread and severe
Cognitive impairments
Severe mood disorders
More pronounced atrophy to frontal,
temporal lobes and anterior thalamus
Greater NFT inclusion of cerebellum and
medulla
Neuronal loss in SN Language difficulties
2/3 subjects have septal
abnormalities
Prominent myelin loss and astrocytosis of WM
in cerebral cortex
Severe spongiosus of
cerebral cortex and
widespread neuronal loss
Visuospatial difficulties
Gait/motor control impairments.
Generalized WM atrophy
LC and SN now pale
Abbreviations: Aβ LC, Locus Coeruleus; NFT, Neurofibrillary Tangle; SN, Substantia Nigra; WM, White Matter.
becomes hyperphosphorylated, which may play a role in the
neurodegeneration of CTE (McKee et al., 2009; Wang et al.,
2013). P-Tau has less affinity for binding with MTs leading to its
abnormal accumulation. P-Tau also induces disassembly of MTs,
which, when coupled with the abnormal accumulation of Tau,
causes significant axonal transport inefficiencies and, ultimately,
neurodegeneration (Khlistunova et al., 2006; Zilka et al., 2006;
Wang et al., 2013). In CTE, the NFTs are predominately
expressed in neurons, but they are also present in lower
quantities in astrocytes and oligodendrocytes (Yoshiyama et al.,
2013).
Though Tau is the hallmark of CTE, it is also involved
in the pathology of a number of other disorders including
Progressive Supranuclear Palsy, Pick’s disease, Corticobasal
degeneration, Frontotemporal dementia, and most notably
in Alzheimer’s disease. However, these tauopathies differ
in topographic distribution of tau, isoform profile, and
phosphorylation state (Williams, 2006) with some being more
similar than others. Among these diseases, CTE is most similar
to AD based on their respective Tau profiles (Schmidt et al.,
2001).
Yet, key differences exist between the histopathology of CTE
and AD. Most of the distinguishing characteristics of CTE’s
Tau profile are related to the spatial distribution of NFTs. NFT
distribution in CTE is sporadic, while AD shows a common and
highly consistent pattern of distribution (Braak and Braak, 1991;
McKee et al., 2009). The perivascular clustering of NFTs and
the prominent presence of NFTS at the depths of sulci are also
unique to CTE (McKee et al., 2013). Greater NFT involvement
in the superior and dorsolateral frontal lobes is present in many
cases of CTE, particularly involving football players (McKee et al.,
2014). Interestingly, this Tau distribution in CTE may match
the biomechanics of head injuries since there is speculation
that the depths of the sulci are areas of stress concentration
for shear forces given that athletes of contact sports experience
frequent high-intensity impacts on the crown of their helmets,
which corresponds to pathological findings in the superior and
dorsal-lateral frontal lobes (Hof et al., 1992; Cloots et al., 2013;
McKee et al., 2014). Notably, this region is also one in which
functional impairments were observed via fMRI in a group of
football players (Talavage et al., 2014). Tau histopathology also
demonstrates the presence of astrocytic tangles in CTE that are
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entirely absent from AD (McKee et al., 2013). Lastly, there is
significantly more WM involvement in CTE than in AD since
axons are relatively spared in AD (McKee et al., 2013), which
could be related to the DAI from concussions and repetitive
subconcussive insults (Johnson et al., 2013b).
Amyloid-beta
Another histopathological difference between CTE and AD is
the presence and distribution of amyloid-Beta (Aβ) (Braak and
Braak, 1991). Though, the extent of Aβ pathology is highly
variable, the relative paucity of Aβ in CTE may be used to help
differentiate the condition from Alzheimer’s disease. Samples
from the VA-BU-SLI Brain Bank showed Aβ in only 27% of
pure CTE cases and in 44% of all CTE cases (including those
with comorbid neurodegenerative diseases) (McKee et al., 2013).
Notably, the cohort of CTE subjects with Aβ were significantly
older than those without Aβ in this study. In this subset of
CTE positive brains, the Aβ was present in the form of diffuse
plaques, neuritic plaques, and vascular plaques (McKee et al.,
2013). More recently, a study investigating the role of Aβ in CTE
found abnormal amyloid deposition in 52% of 114 CTE patients
during post-mortem examination (Stein et al., 2015). This study
also attempts to delineate potential reasons for CTE cases with Aβ
deposition as opposed to those without, while also examining the
potential effects this Aβ pathology may have on other aspects of
the disease. Among the subjects with CTE, this study reports (1)
mean age at time of symptom onset and death were both higher
in CTE subjects with Aβ, (2) Aβ deposition was significantly
associated with presence of APOE e4 allele, (3) Aβ deposition
was correlated more significant Tau deposition independent of
age, and (4) Aβ presence was a strong predictor for both Lewy-
Body co-morbidity and dementia independent of age (Stein
et al., 2015). A comparative analysis was also performed with
non-selected community-based autopsy series of 2332 subjects
without CTE, which showed that the odds of developing Aβ
plaque pathology were 3.8 times higher in CTE than in normal
aging (Stein et al., 2015).
Additionally, the presence of Aβ is not a binary feature; its
regional distribution is significant in distinguishing between CTE
and other neurodegenerative diseases. For example, according
the NIH consensus statement for diagnostic criteria of CTE, the
neuropathologists contend that neurofibrillary degeneration in
the hippocampus caused by Aβ plaques is an exclusion criteria for
diagnosis of CTE (National Institute of Neurological Disorders
and Stroke, 2015). Another key distinction between the Aβ
pathology of CTE and AD is the sulcal predilection of Aβ in
CTE. Researchers have found there was no difference in sulcal
vs. gyral Aβ plaque deposition in subjects with only AD, but
subjects with CTE had significantly greater Aβ plaque burden in
the depths of the sulci (Stein et al., 2015). This could be explained
by greater concentrations of stress at the sulcal depths caused by
the acceleration-deceleration forces in head injuries (Cloots et al.,
2008).
Other
Lewy body and TDP-43 proteinopathy can also coexist with
Tau pathology in CTE, which are the hallmark proteins for
the pathology of Parkinson’s disease and Amyotrophic Lateral
Sclerosis (ALS), respectively. Of the CTE cases identified at the
VA-BU-SLI Brain Bank, 22% had Lewy Pathology (McKee et al.,
2013). TDP-43, however, may be much more common in CTE.
One study found that TDP-43 proteinopathy coexisted with
tauopathy in 80% of their CTE cases (McKee et al., 2010). Those
with TDP-43 pathology are thought to exhibit a subset of CTE,
with motor symptoms progressing at a faster rate in a manner
similar to ALS (McKee et al., 2014). These cases are classified as
CTE-MND, which denotes the comorbid motor neuron disease.
Potential Detection of CTE Pathology with
PET Scans
Positron Emission Tomography (PET) facilitates our
understanding of both normal and abnormal brain function
on a molecular level in real time. It is a powerful molecular
imaging modality that can deliver quantitative measures
of various metabolic processes in the brain with targeted
radiopharmaceuticals (Pike, 2009). These radiotracers emit
positrons, which then undergo radioactive decay before colliding
with electrons to produce 2 photons. The PET scanners are
capable of detecting these photons (gamma rays) in order to
reconstruct an image of spatial density indicative of functional
activity and metabolic processes within the brain (Portnow
et al., 2013). The utility of PET scans is highly adaptable and
its function is contingent on the specific biological process in
question. A large number of neurometabolic processes, that are
often pathological in nature, can be targeted using specifically
developed radioactive tracers.
As the name suggests, these radiopharmaceuticals are usually
labeled with one of the following short-lived positron-emitters:
Carbon-11 (11C) or Fluorine-18 (18F) (Pike, 2009). Brain
PET probes typically have one of two different mechanisms
of action depending on the process they were developed
to examine. The first class radiopharmaceuticals are typically
analogs of endogenous compounds that are designed to enter the
brain via active transport before accumulating upon metabolic
transformation in the brain. The textbook example of such
a probe is 2-[18F]fluoro-2-deoxy-D-glucose (FDG), an analog
of glucose, which can be utilized to measure metabolism in
the brain where glucose is the sole energy source (Pike, 2009;
Gandy et al., 2014). Alternatively, the other class of radioactive
pharmaceuticals is characterized by having no such recognized
transport system and must bind to a specific protein target,
allowing for the detection and quantification of proteins linked
to disease (Pike, 2009). The most well-known example is
Pittsburgh Compound B (PiB), a tracer that provides quantitative
information on Aβ deposition in living human brains (Klunk
et al., 2004). There are now multiple FDA approved amyloid
tracers that are utilized clinically as well as in research.
Imaging Amyloid-beta
The PiB compound, initially developed to track amyloid
deposition in Alzheimer’s disease, has also been utilized to study
Aβ pathology following head trauma. Aβ plaques, a hallmark of
AD, can appear hours within head injury in all age groups and
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are found in up to 30% of patients who die acutely following TBI
(Roberts et al., 1991, 1994; Graham et al., 1995; Ikonomovic et al.,
2004). The deposition of these Aβ plaques, representative of AD,
can occur during “normal aging,” but this process appears to be
accelerated by head injuries (Johnson et al., 2012). Widespread
Aβ deposition increases in cortical gray matter and striatum
of TBI patients (median age of 35 years) between 1 and 361
days following the injury (Hong et al., 2014). Targeting these
plaques with specific radioactive probes via PET can answer
key unknowns regarding the temporal profile of Aβ deposition
following TBI and the subsequent clinical symptomology.
Another PET ligand specific to Aβ, 18F-Florbetapir, is also
being used to investigate the mechanisms of amyloid deposition
following TBI. Using this tracer, one study attempted to examine
the effects of Aβ on cognitive impairment following mTBI by
comparing three cohorts: healthy controls, mTBI with cognitive
impairment, and mTBI with no cognitive impairment. The
PET scans for this study occurred an average of 6 years post-
injury. The results indicate there is significantly greater amyloid
deposition in the mTBI patients exhibiting cognitive dysfunction,
but the cognitively normal mTBI does not significantly differ
from the healthy controls (Yang et al., 2015). These results
either suggest that the cognitively normal mTBI group never
accumulated Aβ following the injury or that they had stronger
neuro protective response that resulted in Aβ clearance following
the head trauma. Future longitudinal studies are required to
better investigate the role of Aβ in both the acute and chronic
phases of recovery from head trauma.
Imaging of Neuroinflammation
It is speculated that the neuroinflammatory processes following
head trauma have deleterious effects over time that may relate to
the pathology characteristic of CTE (Cunningham et al., 2005;
Whitney et al., 2009; Brown and Neher, 2010; Blaylock and
Maroon, 2011). Radiotracers like [11C](R)PK11195 (PK), which
quantitatively measures the presence of activated microglia,
are now being utilized to examine this response in vivo.
One PET study employing this PK ligand indicates a chronic,
perpetual neuroinflammatory response in TBI patients with
significantly increased microglial activation up to 17 years post
injury (Ramlackhansingh et al., 2011). Further, this finding
is substantiated by a separate immunohistochemistry study
reporting elevated microglial activation up to 18 years following
a single head injury (Johnson et al., 2013a). As Blaylock
and Maroon posit, this perpetual inflammatory response could
be the underlying mechanism responsible for triggering the
hyperphosphorylation of Tau and the pathological cascade that
follows (Blaylock and Maroon, 2011).
Developing a Probe for Tau
Researchers should be able to do the same for Tau, specifically
the P-Tau that is a hallmark of CTE, upon the development of
an effective radiopharmaceutical. As of this article’s publication,
a reliable radiotracer to track Tau deposition in vivo is still
under development due to a number of challenging criteria.
In order for the radioactive probes to be suitable for the
quantitative imaging of protein targets in the human brain, they
must exhibit: (1) high affinity for target, (2) high selectivity
for target, (3) high permeability of blood-brain barrier, (4) low
affinity for non-specific binding, (5) absence of confounding
radiometabolites, and (6) suitable pharmacokinetics in relation
to half-life, brain uptake, and washout kinetics (Pike, 2009).
The P-Tau present in CTE presents added unique challenges as
a target for radioactive tracers. First, the P-Tau aggregates are
primarily intracellular, although it is also found extracellularly
upon neuronal death (Jensen et al., 2011; Fodero-Tavoletti et al.,
2012). This implies that the radiotracer must also be permeable
to cell membrane in addition to blood brain barrier (BBB)
in order to bind to P-Tau, which imposes new constraints on
the tracer’s size and lipophilicity. Second, the structure and
morphology of Tau is highly variable making it a much more
complex target than Aβ and other proteins (Jensen et al.,
2011; Fodero-Tavoletti et al., 2012). To further complicate the
matter, Tau aggregates are subject to an array of posttranslational
modifications including acetylation, glycosylation, glycation,
prolyl-isomerization, nitration, and ubiquitination, all of which
have the potential to alter the morphology of Tau and, thus, affect
the ability of specific tracers to bind to it as a target (Fodero-
Tavoletti et al., 2012; Villemagne and Okamura, 2014). Third,
P-Tau shares the same beta-sheet secondary structure as Aβ,
which presents special challenges to developing a radiotracer that
selectively binds to P-Tau (Fodero-Tavoletti et al., 2012).
Scientists are attempting to identify a probe that fits all of these
criteria for the quantitative imaging of P-Tau aggregation. In
2005, Okamura and colleagues screened ∼2000 small molecules
(primarily quinolone and benimidazole derivatives) in an
attempt to find a fitting candidate (Okamura et al., 2005). In
the years since, several of these compounds and others showing
the greatest potential as radiotracers for P-Tau have been serially
analyzed in vitro, ex vivo, and in vivo in animal models. The
compounds that survive the gauntlet of tests with promising
results have the potential to be approved for human trials. The
following section summarizes select probes with the greatest
potential.
FDDNP
The compound 2-(1-(6-[(2-[fluorine-18]fluoroethyl)(methyl)
amino]-2-naphthyl)-ethylidene)malononitrile (FDDNP),
developed in 2002, was the first PET imaging probe capable of
targeting P-Tau. FDDNP showed such promising results in early
in vitro studies that it was deemed suitable to human trials in vivo
to detect P-Tau (Shoghi-Jadid et al., 2002; Agdeppa et al., 2003).
It was the first radiotracer capable of quantitatively measuring
the NFTs of P-Tau in vivo, but it is not specific to P-Tau. FDNNP
also binds to Aβ, which means PET binding may indicate either
the NFTs of P-Tau or Aβ plaque deposits (Small et al., 2006;
Yaqub et al., 2009; Shin et al., 2011). It is unable to distinguish
between Tau and Aβ aggregation, but researchers can make up
for this lack of specificity by combining values from FDNNP
PET with our pre-existing knowledge of regional pattern of Tau
and Aβ deposition observed in various diseases. Additional PET
scans can also be performed with a radiopharmaceutical specific
to Aβ, which researchers can then subtract from FDNNP scan to
differentiate between P-Tau and Aβ.
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Most recently, FDDNP PETwas employed tomeasure Aβ/Tau
deposition in retired NFL players with histories of cognitive
and/or mood symptoms; a group with significant exposure to
head trauma and is at greater risk of CTE. Though the data
is limited by a small sample size, the results from this study
show that FDDNP binding values are significantly greater for
former players in subcortical structures that match the P-Tau
deposition patterns observed in post-mortem examinations of
CTE (Table 1). Furthermore, the FDDNP binding values increase
with the extent of the subject’s concussion history indicating
a correlation with exposure to head trauma (Small et al.,
2013).
18F-THK523
Quinoline and benzimidazole derivatives were identified as
candidates for Tau imaging tracers by screening small molecules
capable of binding to β-sheets resembling the structure
of Tau. THK523, a quinolone derivative, was tagged and
radiolabeled with 18F to be used as a PET probe. In 2011,
the utility of 18F-labeled THK-523 (18F-6-(2-fluoroethoxy)-2-(4-
aminophenyl)quinoline) as a radiotracer was tested in a series
of in vitro, ex vivo, and in vivo experiments in mice. With
the results from these tests, researchers determined that 18F-
THK523 has high selectivity for P-Tau with an overall 5-fold
increase for binding over Aβ with no binding to α-synuclein.
Additionally, the probe was small enough and adequately
lipophilic to penetrate the BBB and cell membrane, while also
exhibiting significantly greater retention in Tau transgenic mice
(Fodero-Tavoletti et al., 2011). Another group of researchers
further examined the selectivity of 18F-THK523 using human
brain tissue from deceased patients of Alzheimer’s disease,
Parkinson’s disease, and several Taupathies (Pick’s disease,
Progressive Supranuclear Palsy, Corticobasal Degeneration). The
results indicate that 18F-THK523 has high selectivity for the P-
Tau found in CTEwith significantly lower selectivity for Aβ, Lewy
bodies, and other Tau variants (Fodero-Tavoletti et al., 2014). The
original developers claim a possible limitation of this probe is
poor pharmacokinetics (slow brain uptake/clearance) based on
their preclinical evaluations (Okamura et al., 2013).
Another group of researchers performed a human clinical
trial to test the utility of 18F-THK523 in an AD population
(Villemagne et al., 2014). As expected from pre-clinical
experiments, 18F-THK523 exhibited strong affinity and
selectivity for Tau in vivo. Global cortical 18F-THK523 binding
provided a robust distinction between AD patients and healthy
controls. Furthermore, the level of 18F-THK523 binding was
significantly correlated with cognitive parameters. A separate
PiB PET scan was employed to demonstrate a marked contrast
in its regional distribution compared to 18F-THK523, and thus
a significant distinction between P-Tau and Aβ pathology. The
researchers also included group of semantic dementia patients,
a disease marked by presence of TDP-43, all of which showed
no binding for 18F-THK523 or PiB (Villemagne et al., 2014).
Interestingly, the results from this clinical trial indicate adequate
brain uptake and clearance to contradict the assertion that this
probe displays poor pharmacokinetics (Okamura et al., 2013).
However, this study highlighted one key limitation that will
preclude 18F-THK523 from becoming a capable radiotracer
for Tau: 18F-THK523 exhibited extremely high white matter
retention. This high nonspecific binding prohibits simple visual
inspection and a great deal of quantitative analysis (Villemagne
et al., 2014).
18F-THK5105 and 18F-THK5117
Using 18F-THK523 as a platform, the original developers
continued compound optimization to develop two novel
compounds within the same family of 18F-labeled arylquinoline
derivatives: 18F-THK5105 and 18F-THK5117 (Okamura et al.,
2013). In vitro binding assays indicate that both THK-5117
and THK-5105 have higher binding affinity for P-Tau than
their predecessor, THK-523 (Okamura et al., 2013). This was
further substantiated by additional experiments in which both
compounds had high binding affinities in specific regions of
AD brain sections that follow the known distribution of Tau
deposition (Okamura et al., 2013). THK5117 and THK5105
also exhibit low nonspecific binding as the binding affinity was
determined to be 25 times lower for Aβ plaques. Additionally,
these newly developed compounds exhibited greatly improved
pharmacokinetics in mice with faster brain uptake and
more rapid clearance as compared with THK-523 (Okamura
et al., 2013). Given its compatibility with the established
criteria for potential PET radiotracers, the researchers recently
selected one of these novel compounds for a human clinical
trial.
18F-THK5105 and 11C-PiB were both employed to investigate
P-Tau and Aβ pathology, respectively, in a PET study of
Alzheimer’s disease patients and age-matched healthy controls
(Okamura et al., 2014). The novel 18F-THK5105 successfully
differentiated AD patients as the radiotracers displayed high
levels of binding in regions that matched the known distribution
of Tau. Additionally, there was high selectivity for Tau with
no 18F-THK5105 binding to Aβ, which was further validated
by the subsequent 11C-PiB scan. Additionally, the level of 18F-
THK5105 binding was significantly correlated with the severity of
dementia. Another interesting finding from this study indicates
that hippocampal atrophy is strongly correlated with 18F-
THK5105 retention, but not 11C-PiB. 18F-THK5105 displayed
pharmacokinetic properties that are superior to all other known
tau radiotracers (THK523, T807, T808, and 11C-PBB3) giving
it a unique advantage. Compared with THK-523, this novel
radiotracer showed improved levels of nonspecific binding with
less WM binding in cortical and subcortical areas. However,
unfavorable non-specific WM retention is still present especially
within the brainstem and thalamus (Okamura et al., 2014).
As a final note, the researchers assert they are optimistic
that they will observe improved pharmacokinetics and enhanced
signal-to-background ratio against WM with 18F-THK5117
based on their findings from pre-clinical experiments (Okamura
et al., 2014). Clinical trials with this compound are currently
ongoing.
18F-T807 and 18F-T808
In the initial screening of compounds, two novel benzimidazole
pyrimidine derivatives were identified for their ability to bind to
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P-Tau and labeled with 18F to create two potential PET probes
for tauopathy: 18F-T807 and 18F-T808 (Shoup et al., 2013). After
in vitro assays with human brain tissue and in vivo experiments
with mice, these novel compounds satisfied all major criteria
for PET radiotracers demonstrating the ability to permeate BBB
& cell membrane, favorable pharmacokinetics, high selectivity
& affinity for P-Tau, and absence of radiometabolites (Zhang
et al., 2012; Xia et al., 2013). Specifically, they exhibited selectivity
that was >27 fold greater for P-Tau over Aβ plaque. Preclinical
studies of these novel compounds also demonstrated minimal
nonspecific white matter binding, which will hopefully translate
to greater clinical utility compared to the previously discussed
radiotracers (Chien et al., 2013).
The first clinical trial employing 18F-T807 was performed on
six human subjects with different cognitive profiles (3 healthy,
2 AD, 1 MCI). 18F-T807 was significantly higher for both patient
populations compared to the controls and, further, the binding
levels were correlated with cognitive function. Additionally,
the pattern of tracer retention overlaps with the known areas
of P-Tau formation according to Braak staging in this patient
population with progressing levels of dementia (1 MCI, 1 mild
AD, 1 severe AD). This proposed tracer also displayed exquisite
selectivity for P-tau over Aβ (>29 fold) in vivo. Significantly,
unlike other 18F PET probes,18F-T807 exhibited very low
non-specific binding in both the gray matter and white matter of
the brain yielding improved contrast and, thus, greater clinical
utility (Chien et al., 2013). These are promising results, but it is
worth noting that this is an incredibly small sample size. Further,
studies are required to validate these findings and, at the time of
publication, there is a large scale clinical trial investigating the
utility of T807 as a Tau tracer.
The same group of researchers went on to perform the
first clinical trial with 18F-T808 shortly after with 11 human
subjects (8 AD, 3 healthy controls). Recall, this compound
showed similar Tau affinity and selectivity as 18F-T807 in
preclinical studies, but it also displayed faster pharmacokinetics
in rodents. The clinical trial corroborated these findings.
Researchers were able to successfully differentiate between AD
patients and healthy controls because of significantly greater
18F-T808 uptake in areas that mirror the known regions of
P-Tau distribution (Chien et al., 2014). Due to the death
of one subject 2 weeks after the PET scan (unrelated to
procedure), an opportunity arose to compare an exploratory
post mortem pathological analysis of the brain tissue to the 18F-
T808 PET scan acquired 2 weeks prior. In this unique case,
the regional distribution and levels of 18F-T808 binding were
consistent with the pathological pattern observed during the
autopsy (Kolb et al., 2013). Similar, to 18F-T807, 18F-T808 also
resulted in low tracer retention in white matter. This yields an
improved contrast that may help clinicians and researchers detect
smaller amounts of tau pathology in the brain. Additionally,
the pharmacokinetics were enhanced compared to 18F-T807,
with 18F-T808 exhibiting more rapid uptake, distribution, and
clearance. However, 18F-T808 does have one key limitation—
it exhibits greater levels of 18F-defluorination, which results in
excessive bone uptake of the tracer and exposure to radiation
(Chien et al., 2014).
11C-PBB3
This PET probe is unlike the rest. It is derived from a
separate class of Tau ligands, phenyl/pyridinyl-butadienyl-
benzothiazoles/benzothiazoliums (PBBs), and it is tagged with
11C as opposed to 18F (Maruyama et al., 2013). There are
advantages and disadvantages associated with each of these
radiolabels. 18F radiolabels are typically preferred due to their
convenience. They have a longer half-life (110min) and can
be synthesized at a central production center before being
distributed to the study site(s). 11C has a much shorter half-life
(20min) that precludes this regional distribution. However, the
11C radiolabel permits two or more serial scans to be conducted
on the same subject with different radiopharmaceuticals on the
same day just several hours apart (Mathis and Klunk, 2013).
This is beneficial for researchers and clinicians interested in
performing consecutive PET scans with 11C-PBB3 and 11C-PiB.
Several PBB candidates were exposed to thorough preclinical
evaluation and PBB3 was the compound that best fulfilled the
criteria for radiopharmaceuticals. As such, a clinical trial was
developed to test its utility as a diagnostic marker for tauopathies
in a study with six adult subjects (3 AD, 3 Healthy). The results
were promising. There were distinct binding patterns for both
11C-PBB3 and 11C-PiB that match the expected P-Tau and Aβ
pathology, respectively. There was a correlation between 11C-
PBB3 binding and cognitive deficits that was absent with the 11C-
Pib data. The 11C-PBB3 exhibited adequate contrast with limited
nonspecific binding to white matter, however, it accumulated
in the dural venous sinuses for both the AD patients and the
controls (Maruyama et al., 2013). An ancillary finding resulted
from additional 11C-PBB3 and 11C-PiB PET scans of a subject
who was clinically diagnosed with corticobasal degeneration.
For this subject, 11C-PiB stayed at the control level, but there
was increased retention of 11C-PBB3 in the basal ganglia. This
indicates that 11C-PBB3 is specific to Tau, but it might bind
to conformations other than what is expected in CTE and AD
populations (Maruyama et al., 2013).
Discussion and Future Directions
There is tremendous potential clinical utility in both detecting
and quantifying changes of P-Tau aggregation. When a reliable
and effective radiopharmaceutical is available for P-Tau, PET
will be a vital tool for researchers to uncover the underlying
pathological processes of CTE. At risk populations, like athletes
of contact sports, should be tracked longitudinally to improve our
understanding of disease mechanisms even prior to exhibiting
signs and symptoms of CTE. Pre-clinical phenotypes might exist
that could be identified to treat at-risk populations before their
underlying pathology progresses to CTE. Further, symptoms of
individuals presenting with the signs of CTE can be observed over
time as a function of Tau pathology.
Rather than solely relying on PET, longitudinal studies should
also employ multimodal neuroimaging techniques. PET scans
will provide terrific insight into the disease mechanisms and
pathogenic cascade, but for several reasons it is unlikely to
be the long term answer for clinical diagnosis. Unlike MRI,
PET is invasive and associated with greater risks stemming
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from radiation exposure. Radiopharmaceuticals are not only
expensive, but also difficult to synthesize and transport in timely
fashion. Once a reliable and effective Tau radiopharmaceutical is
developed, it would be best to use PET in conjunction with other
MRI modalities. When used in combination, the findings from
PET scans may be strongly correlated with structural MRI, DTI,
and fMRI results to the extent where entirely new biomarkers will
be established for CTE that solely rely on MRI modalities.
It is also important to build on our current understanding
of CTE by more appropriately employing the technologies
that are already available to us. For example, the majority of
DTI studies investigating the effects of concussions are done
0–6 months post injury. They are fairly consistent in showing
impaired WM integrity with conflicting findings primarily
resulting from studies of the hyperacute response to head trauma
just 1–5 days after injury (Niogi and Mukherjee, 2010). The few
studies utilizing DTI to investigate the chronic effects of head
trauma >2 years post-injury report significantly impaired WM
integrity that correlates with cognitive impairment (Kraus et al.,
2007; Geary et al., 2010; Little et al., 2010). It is plausible that
much of the damage done to the axons occurs secondarily to
the initial injury through complex biological mechanisms that
may not be observable in the early phases of recovery (Morley
and Seneff, 2014). It is important for future studies to observe
those with frequent exposure to head trauma longitudinally,
even after exposure to head trauma has ended. The initial insult
of the injury(s) may incur perpetual neuronal damage due to the
underlying immunoexcitatory response many years after the last
subconcussive insult, which has be documented 18 years after
the initial head injury (Ramlackhansingh et al., 2011; Johnson
et al., 2013a). If this is the case, then clinicians may have the
potential to stop ongoing neuronal damage from progressing to
a full blown neurodegenerative disease. This has already been
demonstrated in mice: the reduction of NFTs and Aβ levels (but
not Aβ alone) resulted in improved neuronal health while also
ameliorating cognitive decline and improving motor function
(Oddo et al., 2006).
For this reason, another immediate application of this PET
technology will be quantitatively measuring the effectiveness and
utility of drugs capable of targeting NFTs. If this Tau mediated
neurodegeneration is detected and properly treated, cognitive
function and overall mental health can potentially be restored.
There are several therapeutic strategies to treat Tau mediated
neurodegeneration that are currently being explored.
Conclusion
There is mounting evidence that TBI or significant exposure
to repetitive subconcussive insults (or any combination of the
two) may trigger a pathological cascade that results in abnormal
accumulation of P-Tau, which may ultimately manifest as CTE.
At this time, however, there are many limitations that must be
addressed to better understand this disease. First, brain banks
like the VA-BU-SLI investigating CTE are conducting studies
on biased samples that lack low-exposure subjects, making it
difficult to extrapolate incidence rates. Second, there is currently
no way to diagnose CTE in vivo, which prevents tracking
symptoms as they progress. Third, because awareness is still
relatively low and symptoms overlap with other disorders (i.e.,
AD, ALS), CTE can easily be misdiagnosed. Fourth, inaccurate
medical records of concussion history based on ambiguous
definitions and diagnostic criteria, makes the correlation between
head injuries and neurodegenerative diseases difficult to assess
retrospectively. Fifth, there is a large knowledge gap in non-head
trauma risk factors that may make individuals more susceptible
to CTE. Despite these limitations, the existing scientific evidence
increasingly supports that exposure to high levels of “total brain
trauma” contributes to the unique pathology observed in CTE.
Nevertheless, we need to be honest and forthcoming with these
limitations. With the recent high-profile cases of CTE, the media
has begun to sensationalize this disease, which means researchers
and clinicians need to proceed with caution, particularly when
counseling patients with significant exposure to head trauma.
The gaps in knowledge created by these limitations are rapidly
diminishing and will continue to do so. The most pressing
issue, however, is developing an in vivo diagnostic tool capable
of detecting CTE. Such a tool should be used in conjunction
with other, more readily available, neuroimaging modalities (e.g.,
MRI) to establish an additional stand-alone biomarker for CTE.
With a reliable in vivo diagnostic tool, there would be a more
accurate prediction of disease prevalence and we could, for
the first time, track the progression of disease pathology and
symptomology through longitudinal studies. Additionally, it will
be vital for clinicians to differentiate between CTE and other
neurodegenerative diseases, particularly since mortality from
neurodegenerative diseases is significantly greater in populations
with high levels of “total brain trauma.” Improved differential
diagnosis will increase the likelihood that patients receive the
appropriate treatment. Lastly, such a tool to would rapidly
accelerate our ability to design therapeutic strategies capable of
preventing and treating this debilitating disease.
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